Skip to content

Identification of sensitization sites of keloid radiotherapy based on single-cell sequencing technology and related clinical and mechanistic studies

Identification of sensitization sites of keloid radiotherapy based on single-cell sequencing technology and related clinical and mechanistic studies

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068137
Enrollment
Unknown
Registered
2023-02-08
Start date
2023-02-08
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Keloid

Interventions

Conventional electron beam radiotherapy group:Postoperative continuous radiotherapy for 4 days (single 5Gy, total 20Gy)
Traditional 90 strontium isotope radiotherapy group:Postoperative continuous radiotherapy for 4 days (1400 cGy for a single time, 4 times for a course of treatment, total dose 5600-7000cGy)

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria included inclusion criteria including female patients; Age in 20-40 years; The onset of keloids is less than or equal to 5 years; keloids located on the chest; Keloids are more symmetrically distributed on both sides of the midline; The keloid bulge = 3mm thick. Explain the complications and prognosis related to surgery and radiotherapy to all patients, and sign all relevant informed consent forms. Twenty patients were required to be included in this study.

Exclusion criteria

Exclusion criteria: Specific exclusion criteria include pregnant and lactating patients who have received preoperative treatment such as injection therapy and laser therapy; keloids secondary to surgical operations (such as heart valve replacement and endoscopic surgery), trauma and burns, etc.; postoperative Recurrent keloids; keloids with signs of infection; patients not receiving the radiotherapy regimen set by the study; patients with systemic diseases that are not suitable for surgical resection, etc.

Design outcomes

Primary

MeasureTime frame
Keloid prognosis;

Countries

China

Contacts

Public ContactXu Xuewen

West China Hospital, Sichuan University

xxw_0826@163.com18980601856

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026